Cancer nanotargeted radiopharmaceuticals for tumor imaging and therapy

Anticancer Research

Volumn 29, Issue 10, 2009, Pages 4107-4118

  Ting, Gann ^a   Chang, Chih Hsien ^b   Wang, Hsin Ell ^c  

^a NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^b INSTITUTE OF NUCLEAR ENERGY RESEARCH   (Taiwan)

^c NATIONAL YANG MING UNIVERSITY   (Taiwan)

Author keywords

Cancer therapy; Nanocarriers; Nanotargeted radiopharmaceuticals; Review; Tumor imaging

Indexed keywords

1,4,7,10 TETRAAZACYCLODODECANE 1,4,7,10 TETRAACETIC ACID; ACTINIUM 225; ARGINYLGLYCYLASPARTIC ACID; CARBON NANOTUBE; COPPER 64; COPPER 67; DENDRIMER; FLUORINE 18; GALLIUM 67; IBRITUMOMAB TIUXETAN; INDIUM 111; IODINE 123; IODINE 131; IRON OXIDE; LIPOSOME; LUTETIUM 177; NANOCARRIER; NANOPARTICLE; OXIME; PENTETATE INDIUM IN 111; QUANTUM DOT; RADIOISOTOPE; RADIOPHARMACEUTICAL AGENT; RHENIUM 186; RHENIUM 188; RITUXIMAB; TECHNETIUM 99M; TOSITUMOMAB I 131; UNINDEXED DRUG; YTTRIUM 90;

CANCER DIAGNOSIS; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER THERAPY; CONJUGATION; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG HALF LIFE; DRUG SAFETY; HUMAN; ISOTOPE LABELING; NANOMEDICINE; NANOTECHNOLOGY; NEAR INFRARED SPECTROSCOPY; NONHODGKIN LYMPHOMA; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; TUMOR VOLUME;

ANIMALS; HUMANS; NANOSTRUCTURES; NEOPLASMS; RADIOPHARMACEUTICALS;

EID: 71949095322     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Garcia M, Jemal A, Ward EM, Center MM, Hao Y, Siegel RL and Thun MJ: Global Cancer Facts and Figures. American Cancer Society 2008.
2. Strebhardt K and Ullrich A: Paul Ehrlich's magie bullet concept: 100 years of progress. Nat Rev Cancer 8: 473-480, 2008. (Pubitemid 351752547)
3. Adams GP and Weiner LM: Monoclonal antibody therapy of cancer. Nat Biotechnol 23: 1147-1157, 2005.
4. Reichert JM and Valge-Archer VE: Development trends for monoclonal antibody cancer therapeutics. Nat Rev Drug Discov 6: 349-356, 2007. (Pubitemid 46696550)
5. Carter PJ: Potent antibody therapeutics by design. Nat Rev Immunol 6: 343-357, 2006.
6. Allen TM and Cullis PR: Drug delivery systems: entering the mainstream. Science 303: 1818-1822, 2004.
7. Davis ME, Chen ZG and Shin DM: Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 7: 771-782, 2008.
8. Ferrari M: Cancer nanotechnology: opportunities and challenges. Nat Rev Cancer 5: 161-171, 2005.
9. Lammers T, Hennink WE and Storm G: Tumour-targeted nanomedicines: principles and practice. Br J Cancer 99: 392-397, 2008.
10. Sanhai WR, Sakamoto JH, Canady R and Ferrari M: Seven challenges for nanomedicine. Nat Nanotechnol 5: 242-244, 2008.
11. Milenic DE, Brady ED and Brechbiel MW: Antibody-targeted radiation cancer therapy. Nat Rev Drug Discov 5: 488-499, 2004.
12. 131I-tositumomab. Oncogene 26: 3614-3628, 2007. (Pubitemid 46842712)
13. Macklis RM and Pohlman B: Radioimmunotherapy for non-Hodgkin's lymphoma: a review for radiation oncologists. Int J Radiat Oncol Biol Phys 66: 833-841, 2006.
14. 131I-tositumomab in clinical practice. J Nucl Med 48: 1767-1776, 2007. (Pubitemid 350099320)
15. Wong JY: Systemic targeted radionuclide therapy: potential new areas. Int J Radiat Oncol Biol Phys 66: S74-82, 2006.
16. Mitra A, Nan A, Line BR and Ghandehari H: Nanocarriers for nuclear imaging and radiotherapy of cancer. Curr Pharm Des 12: 4729-4749, 2006. (Pubitemid 44841764)
17. Hamoudeh M, Kamleh MA, Diab R and Fessi H: Radionuclides delivery systems for nuclear imaging and radiotherapy of cancer. Adv Drug Deliv Rev 60: 1329-1346, 2008.
18. Carlsson J, Forssell Aronsson E, Hietala SO, Stigbrand T and Tennvall J: Tumour therapy with radionuclides: assessment of progress and problems. Radiother Oncol 66: 107-117, 2003. (Pubitemid 36321806)
19. 111In-labeled EGF is selectively radiotoxic to human breast cancer cells overexpressing EGFR. J Nucl Med 41: 429-438, 2000. (Pubitemid 30133961)
20. Phillips WT: Delivery of gamma-imaging agents by liposomes. Adv Drug Deliv Rev 37: 13-32, 1999.
21. Boerman OC, Laverman P, Oyen WJ, Corstens FH and Storm G: Radiolabeled liposomes for scintigraphic imaging. Prog Lipid Res 39: 461-475, 2000.
22. 111In-labeled epidermal growth factor administered to athymic mice bearing epidermal growth factor receptor-positive human breast cancer xenografts. J Nucl Med 44: 1469-1478, 2003. (Pubitemid 39663362)
23. 111In-DTPA-human epidermal growth factor: an auger electron-emitting radiotherapeutic agent for epidermal growth factor receptor-positive breast cancer. J Nucl Med 47: 1023-1031, 2006. (Pubitemid 46939956)
24. Huwyler J, Drewe J and Krahenbuhl S: Tumor targeting using liposomal antineoplastic drugs. Int J Nanomedicine 3: 21-29, 2008.
25. Kleiter MM, Yu D, Mohammadian LA, Niehaus N, Spasojevic I, Sanders L, Viglianti BL, Yarmolenko PS, Hauck M, Petry NA, Wong TZ, Dewhirst MW and Thrall DE: A tracer dose of technetium-99m-labeled liposomes can estimate the effect of hyperthermia on intratumoral doxil extravasation. Clin Cancer Res 12: 6800-6807, 2006. (Pubitemid 44876850)
26. Harrington KJ, Mohammadtaghi S, Uster PS, Glass D, Peters AM, Vile RG and Stewart JS: Effective targeting of solid tumors in patients with locally advanced cancers by radiolabeled pegylated liposomes. Clin Cancer Res 7: 243-254, 2001. (Pubitemid 32183025)
27. Oku N: Delivery of contrast agents for positron-emission tomography imaging by liposomes. Adv Drug Deliv Rev 37: 53-61, 1999.
28. 177Lu- pegylated liposomes conjugates in tumor-bearing mice. Nucl Instrum Meth A 569: 533-537, 2006. (Pubitemid 44820481)
29. 111In-VNB-liposome on human colorectal adenocarcinoma HT-29/luc mouse xenografts. Nucl Instrum Meth A 569: 497-504, 2006. (Pubitemid 44820476)
30. Elbayoumi TA and Torchilin VP: Enhanced accumulation of long-circulating liposomes modified with the nucleosome-specific monoclonal antibody 2C5 in various tumours in mice: gamma-imaging studies. Eur J Nucl Med Mol Imaging 33: 1196-1205, 2006.
31. 111In-labeled polychelating-polymer- containing immunoliposomes. Mol Pharm 3: 525-530, 2006. (Pubitemid 44639129)
32. 111In nanoparticles. Int J Cancer 120: 1951-1957, 2007.
33. McDevitt MR, Chattopadhyay D, Kappel BJ, Jaggi JS, Schiffman SR, Antczak C, Njardarson JT, Brentjens R and Scheinberg DA: Tumor targeting with antibody-functionalized, radiolabeled carbon nanotubes. J Nucl Med 48: 1180-1189, 2007. (Pubitemid 47052659)
34. Cai W, Chen K, Li ZB, Gambhir SS and Chen X: Dual-function probe for PET and near-infrared fluorescence imaging of tumor vasculature. J Nucl Med 48: 1862-1870, 2007.
35. Chen K, Li ZB, Wang H, Cai W and Chen X: Dual-modality optical and positron emission tomography imaging of vascular endothelial growth factor receptor on tumor vasculature using quantum dots. Eur J Nucl Med Mol Imaging 35: 2235-2244, 2008.
36. Lee HY, Li Z, Chen K, Hsu AR, Xu C, Xie J, Sun S and Chen X: PET/MRI dual-modality tumor imaging using arginine-glycine-aspartic (RGD)-conjugated radiolabeled iron oxide nanoparticles. J Nucl Med 49: 1371-1379, 2008.
37. Emfietzoglou D, Kostarelos K and Sgouros G: An analytic dosimetry study for the use of radionuclide-liposome conjugates in internal radiotherapy. J Nucl Med 42: 499-504, 2001. (Pubitemid 32207403)
38. 186Re-SNS/S complexes: in vitro stability, imaging, and biodistribution in rats. J Nucl Med 44: 1992-1999, 2003.
39. 99mTc labeling of pegylated liposomal doxorubicin (Doxil) for pharmacokinetic and non-invasive imaging studies. J Pharmacol Exp Ther 308: 419-425, 2004. (Pubitemid 38134199)
40. Phillips WT, Goins B and Bao A: Radioactive liposomes. Wiley Interdiscipl Rev Nanomed Nanobiotechnol 1: 69-83, 2009.
41. 186Re-liposome radionuclide therapy in a head and neck squamous cell carcinoma xenograft positive surgical margin model. Clin Cancer Res 14: 3975-3983, 2008.
42. Phillips WT, Klipper R and Goins B: Novel method of greatly enhanced delivery of liposomes to lymph nodes. J Pharmacol Exp Ther 295: 309-313, 2000. (Pubitemid 30746097)
43. Harrington KJ, Rowlinson-Busza G, Syrigos KN, Vile RG, Uster PS, Peters AM and Stewart JS: Pegylated liposome-encapsulated doxorubicin and cisplatin enhance the effect of radiotherapy in a tumor xenograft model. Clin Cancer Res 6: 4939-4949, 2000. (Pubitemid 32110440)
44. Huber PE, Bischof M, Jenne J, Heiland S, Peschke P, Saffrich R, Grone HJ, Debus J, Lipson KE and Abdollahi A: Trimodal cancer treatment: beneficial effects of combined antiangiogenesis, radiation, and chemotherapy. Cancer Res 65: 3643-3655, 2005. (Pubitemid 40616341)
45. Lammers T, Subr V, Peschke P, Kuhnlein R, Hennink WE, Ulbrich K, Kiessling F, Heilmann M, Debus J, Huber PE and Storm G: Image-guided and passively tumour-targeted polymeric nanomedicines for radiochemotherapy. Br J Cancer 99: 900-910, 2008.
46. 188Re-BMEDA-liposome in a C26 murine colon carcinoma solid tumor animal model. Anticancer Res 27: 2217-2225, 2007. (Pubitemid 47228056)
47. 188Re-BMEDA-labeled pegylated liposomes after intraperitoneal injection in a C26 colon carcinoma ascites mouse model. Nucl Med Biol 34: 415-423, 2007.
48. 188Re-DXR-liposome in C26 colon carcinoma ascites mice model. Nucl Med Biol 35: 883-893, 2008.
49. 111In-vinorelbine-liposomes in a human colorectal carcinoma HT-29/luc-bearing animal model. Nucl Med Biol 35: 623-634, 2008. (Pubitemid 351853430)
50. 188Re-(DXR) -liposome for internal radiotherapy. Cancer Biother Radiopharm 23: 749-758, 2008.
51. Kostarelos K and Emfietzoglou D: Tissue dosimetry of liposome- radionuclide complexes for internal radiotherapy: toward liposome-targeted therapeutic radiopharmaceuticals. Anticancer Res 20: 3339-3345, 2000. (Pubitemid 30802717)
52. Syme AM, McQuarrie SA, Middleton JW and Fallone BG: Dosimetric model for intraperitoneal targeted liposomal radioimmunotherapy of ovarian cancer micrometastases. Phys Med Biol 48: 1305-1320, 2003.
53. Sofou S, Thomas JL, Lin HY, McDevitt MR, Scheinberg DA and Sgouros G: Engineered liposomes for potential alpha-particle therapy of metastatic cancer. J Nucl Med 45: 253-260, 2004. (Pubitemid 47618645)
54. 225Ac in rigid liposomes for potential targeted therapy of micrometastases. Bioconjug Chem 19: 1274-1282, 2008. (Pubitemid 351874951)
55. Sofou S, Kappel BJ, Jaggi JS, McDevitt MR, Scheinberg DA and Sgouros G: Enhanced retention of the alpha-particle-emitting daughters of actinium-225 by liposome carriers. Bioconjug Chem 18: 2061-2067, 2007. (Pubitemid 350220009)
56. 90Y-labeled nanoparticles. Int J Radiat Oncol Biol Phys 58: 1215-1227, 2004. (Pubitemid 38314807)
57. Shukla S, Wu G, Chatterjee M, Yang W, Sekido M, Diop LA, Muller R, Sudimack JJ, Lee RJ, Barth RF and Tjarks W: Synthesis and biological evaluation of folate receptor-targeted boronated PAMAM dendrimers as potential agents for neutron capture therapy. Bioconjug Chem 14: 158-167, 2003. (Pubitemid 36169029)
58. Yanagie H, Maruyama K, Takizawa T, Ishida O, Ogura K, Matsumoto T, Sakurai Y, Kobayashi T, Shinohara A, Rant J, Skvarc J, Ilic R, Kuhne G, Chiba M, Furuya Y, Sugiyama H, Hisa T, Ono K, Kobayashi H and Eriguchi M: Application of boron-entrapped stealth liposomes to inhibition of growth of rumour cells in the in vivo boron neutron-capture therapy model. Biomed Pharmacother 60: 43-50, 2006. (Pubitemid 41821218)